Rodgers Silicon Valley Acquisition Corp. (NASDAQ:RSVA) announced in a press release today that its shareholders approved its combination with next-generation 3D Silicon™ Lithium-ion battery manufacturer Enovix at a special meeting held on July 12.
The release did not include redemption numbers, but Rodgers Silicon Valley traded above $20 throughout July 8, the day of its redemption deadline, and opened today at $22.04.
The combined entity’s shares and warrants will start trading on the Nasdaq under the new symbols “ENVX” and “ENVXW”, respectively, on Thursday, July 15.
The transaction resulted in approximately $405 million of gross cash proceeds, before expenses, which will allow Enovix to build out its first two production facilities to support demand from blue chip customers in the global mobile computing market while continuing to develop cells for Electric Vehicles (EVs).
Rodgers Silicon Valley and Enovix initially announced the $1.128 billion deal on February 22. Enovix’s initial goal is to provide designers of category-leading mobile devices with a high-energy battery so they can create more innovative and effective portable products. The company is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable widespread utilization of renewable energy.
Battery technology companies have been hot. Quantumscape (NYSE:QS), also a battery cell technology company, announced its $3.3 billion deal with Kensington (NYSE:KCAC) a few months prior to Evonix back in September where the markets soared in response to the news. RSVA struck while the iron was still hot as it was able to negotiate PIPE investors up to $14 per share in hopes that it would be next Quantumscape deal. QS’s deal successfully closed with low redemptions in late November and opened today at $24.28.
Enovix ramped up hiring last week with five new additions to its leadership team to accelerate expansion ahead of the closing of its deal.
ADVISORS
- Oppenheimer & Co. Inc. is serving as financial advisor to Rodgers Silicon Valley Acquisition Corp.
- Loeb & Loeb LLP is serving as legal advisor to Rodgers Silicon Valley Acquisition Corp.
- Oppenheimer & Co. Inc. and Williams Trading, LLC are serving as placement agents on the PIPE offering.
- Cooley LLP is serving as legal advisor to Enovix
- Winston & Strawn LLP is serving as legal advisor to the placement agents.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...